|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Such ROS-dependent chemiluminescence of SPN allows ROS generation within a tumor to be optically monitored during the CDT process.
|
31777250 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we report the histological presentation of 6 Spitz tumors with ROS1 fusion.
|
31361613 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with EGFR-mutant NSCLC, ROS1-rearranged tumors were more likely to exhibit imaging features of lymphangitic carcinomatosis (ROS1, 42%; EGFR, 12%; P < .01) and less likely to have air bronchograms in the primary tumor (ROS1, 2%; EGFR, 28%; P < .01).
|
31708389 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Low penetration depth of excited light, undesirable distribution of photosensitizers, severe hypoxia, and inefficient reactive oxygen species (ROS) generation in tumors, lead to the poor therapeutic effects in photodynamic therapy.
|
31566306 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, an amplified oxidative damage strategy for tumor therapy was proposed that was focused not only on the enhancement of ROS generation but also the inhibition of subsequent MTH1 enzyme activity simultaneously.
|
31262183 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we have summarized the sources of ROS generation in cancer cells, its role in the tumor microenvironment, the possible functions of ROS and its important scavenger systems in tumor progression with special emphasis on solid tumors.
|
30905813 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Great progress has also been made regarding novel nanoparticle-mediated therapies to enhance tumor cell death via ROS generation and angiogenic inhibition.
|
28990403 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nanoceria decorated flower-like molybdenum sulphide nanoflakes: an efficient nanozyme for tumour selective ROS generation and photo thermal therapy.
|
31225848 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy.
|
31313100 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutic outcomes of PDT rely on ROS generation in a tumor microenvironment, which can be controlled with dual selectivity by localization of the photosensitizer and confinement of light to the targeted tumor microenvironment.
|
31066391 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Under fluorescence imaging guidance, the first-wave of NIR laser irradiation induce reactive oxygen species (ROS) generation, trigger cleavage of the polyethylene glycol (PEG) corona, and thus promote tumor retention and deep penetration of LINC.
|
31423683 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A thorough understanding of ROS1 rearrangement-related histologic features would be helpful to identify ROS1-rearranged tumors in advanced-stage NSCLC.
|
31085007 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After selective tumor irradiation, an almost complete eradication of the tumor can be reached as a consequence of reactive oxygen species (ROS) generation, which not only damage tumor cells, but also lead to tumor-associated vasculature occlusion and the induction of an immune response.
|
31362060 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ROS1 siRNA with its potential therapeutic role in treating 4T1-induced breast tumor was selected for subsequent in vivo tumor regression study, revealing that ROS1 siRNA-loaded SSNs exerted more significant anti-tumor effects than Na-Glc-SSNs carrying the same siRNA following intravenous administration, without any systemic toxicity.
|
30791612 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both <i>in vitro</i> cellular assays and <i>in vivo</i> tumor-xenograft experiments demonstrated the efficient Cu-enhanced and tumor-specific chemotherapeutic efficacy of DSF, with cocontributions from highly toxic CuET complexes and ROS generated within tumors.
|
31251050 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Entrectinib (Rozlytrek<sup>®</sup>) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1, 2 and 3, respectively], c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) with central nervous system (CNS) activity developed by Roche for the treatment of various solid tumours harbouring NTRK1/2/3 or ROS1 gene fusions.
|
31372957 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The efficiency of photosensitizers in tumor photodynamic therapy (PDT) often compromises their poor water solubility, low extinction coefficients, photobleaching, and dissatisfactory reactive oxygen species (ROS) generation efficiency.
|
31710076 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, various new nanomaterial-mediated radiosensitive approaches have been successively reported, such as catalyzing reactive oxygen species (ROS) generation, consuming intracellular reduced glutathione (GSH), overcoming tumor hypoxia, and various synergistic radiotherapy ways.
|
30156333 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reactive oxygen species (ROS) generated in these conditions play an important role in the initiation and promotion of neoplastic growth.
|
31781331 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of 16 patients assayed known to harbor anALK, ROS1, or RET in tumor, G360 detected fusions in 7 cases, ctDx-Lung detected fusions in 13 cases, and 3 cases were detected by neither.
|
31320002 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The preparation of the H<sub>2</sub>O<sub>2</sub>-activated oxidative stress amplifier is a convincing strategy for promoting intracellular ROS generation and enhancing the tumor PDT efficacy, which could also augment the clinical application of PDT.
|
31621699 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
From August 2013 to March 2018, 5606 patients had their tumour tested for crizotinib targeted molecular alterations: 252 patients had c-MET ≥ 6 copies, 74 c-MET-mutation, and 78 ROS-1-translocated tumour.
|
31584608 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When the tumor tissues were subjected to 660 nm irradiation, reactive oxygen species (ROS) generated by Ce6 induced the rapid degradation of the adjacent <i>TK</i> bond, resulting in PEG detachment and enhanced tumor cell internalization.
|
31754398 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, further advancements including tumor selectivity and ROS generation efficiency are still required.
|
31067008 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In particular, robust IHC assays performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissue are widely used as surrogate markers for ALK and ROS1 rearrangements and for detecting programmed death ligand 1 (PD-L1) expression in patients with advanced NSCLC; in addition, they have become essential for treatment decisions.
|
31050216 |
2019 |